# Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/sintilimab-plus-bevacizumab-biosimilar-ibi305-and-chemotherapy-for-patients-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shun Lü,Lin Wu,Hong Jian,Ying Chen,Qiming Wang,Jian Fang,Ziping Wang,Yanping Hu,Meili Sun,Liang Han,Liyun Miao,Cuimin Ding,Jiuwei Cui,Baolan Li,Yueyin Pan,Xingya Li,Feng Ye,Anwen Liu,Ke Wang,Shundong Cang,Hui Zhou,Xing Sun,David Ferry,Yong Lin,Shuyan Wang,Wen Zhang,Chengli Zhang |
| Citations | 251 |
| DOI | 10.1016/s1470-2045(22)00382-5 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4288459215 |
| PMID | 35908558 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Lin Wu](https://scholariq.org/researchers/lin-wu/)
- [Ke Wang](https://scholariq.org/researchers/ke-wang/)
- [Hong Jian](https://scholariq.org/researchers/hong-jian/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.